STAMFORD, Conn.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq:DCTH) today announced that the Company has signed a five year extension to its Cooperative Research and Development Agreement (“CRADA”) with the National Cancer Institute (“NCI”). This extension enhances and expands the initial CRADA that expired in December 2006. The new five year extension provides for the Company and the NCI to collaborate in the joint development and evaluation of the Delcath Systems device to deliver high-dose Melphalan to patients, and to evaluate the advisability of developing additional commercial agents for use with the Delcath System, the Company’s percutaneous perfusion technology for region-specific delivery of chemotherapeutic and other therapeutic agents.
